KAT6A and leukemia: Alternatively, it has been proposed that the ability of MOZ-TIF2 to deplete CBP, particularly from the promyelocytic leukemia (PML) bodies, results in subversion of normal gene expression leading to development of leukemia 14, 15, 16.